Evidências científicas sobre a hepatite Delta no Brasil: revisão integrativa da literatura

Oliveira, Marcelo Siqueira de; Valle, Suiane da Costa Negreiros do; Souza, Rodrigo Medeiros de; Silva, Romeu Paulo Martins; Figueiredo, Elisabeth Níglio de; Taminato, Mônica; Fram, Dayana Souza

doi:10.1590/1982-0194201700091

Cited by 5 publications

(3 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HDV infection only occurs in humans already infected with HBV, often leading to the rapid development of serious liver conditions such as cirrhosis, hepatocellular cancer, and fulminant hepatitis. Despite these high endemic indicators in the north of the country, this condition is still neglected by health services 27 .…”

Section: Discussionmentioning

confidence: 99%

Hepatitis mortality in Brazil and regions, 2001–2020: temporal trend and spatial analysis

Sousa

Santos

Oliveira

et al. 2023

Rev. bras. epidemiol.

View full text Add to dashboard Cite

Objective: To analyze the spatial distribution and the temporal trend of the hepatitis mortality rate in Brazil from 2001 to 2020. Methods: Ecological, temporal, and spatial study on mortality from hepatitis in Brazil with data from the Mortality Information System (Sistema de Informações sobre Mortalidade – SIM/DATASUS). Information was stratified by year of diagnosis, region of the country, municipalities (of residence). Standardized mortality rates (SMR) were calculated. The temporal trend was estimated by Prais-Winsten regression and the spatial distribution by the Global Moran Index (GMI). Results: The highest SMR means in Brazil were for Chronic viral hepatitis with 0.88 deaths per 100,000 inhabitants (SD=0.16), followed by Other viral hepatitis with 0.22/100,000 (SD=0.11). In Brazil, the temporal trend of mortality from Hepatitis A was −8.11% per year (95%CI −9.38; −6.82), while for Hepatitis B it was −4.13% (95%CI −6.03; −2.20), of Other viral hepatitis of −7.84% (95%CI −14.11; −1.11) and of Unspecified Hepatitis −5.67% per year (95%CI −6.22; −5.10). Mortality due to chronic viral hepatitis increased by 5.74% (95%CI 3.47; 8.06) in the North and 4.95% in the Northeast (95%CI 0.27; 9.85). The Moran Index (I) for Hepatitis A was 0.470 (p<0.001), for Hepatitis B 0.846 (p<0.001), Chronic viral hepatitis=0.666 (p<0.001), other viral hepatitis=0.713 (p<0.001), and Unspecified Hepatitis=0.712 (p<0.001). Conclusion: The temporal trend of hepatitis A, B, other viral, and unspecified hepatitis was decreasing in Brazil, while mortality from chronic hepatitis was increasing in the North and Northeast.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis mortality in Brazil and regions, 2001–2020: temporal trend and spatial analysis

Sousa

Santos

Oliveira

et al. 2023

Rev. bras. epidemiol.

View full text Add to dashboard Cite

show abstract

“…No Egito chega a infectar cerca de 20,0% da população, na Ásia sua prevalência chega a 82,0%. Na América do Sul sua maior distribuição encontra-se na bacia amazônica, destacando-se a Amazônia ocidental brasileira onde observamos até 85,0% dos pacientes infectados (Oliveira et al, 2017).…”

Section: Hepatite D (Hdv)unclassified

Panorama das hepatites virais: um estudo atual

Sousa

Farias

Macedo

et al. 2020

RSD

View full text Add to dashboard Cite

As Hepatites Virais (HV) são causadas por cinco tipos distintos de vírus que possuem tropismo pelo tecido hepático, apresentando importantes diferenças entre si e particularidades regionais. Dessa forma, o presente estudo objetiva realizar um levantamento bibliográfico atual, disseminando informações sobre aspectos epidemiológicos, manifestações clínicas, formas preventivas, testagem e tratamento das HVs. Esse estudo trata-se de uma revisão bibliográfica, qualitativa, com característica exploratória, onde foram realizadas buscas nas bases de dados virtuais por artigos, dissertações, teses, manuais e boletins epidemiológicos no período de 2010 a 2020. As HVs são doenças infecciosas sistêmicas, consideradas as principais representantes da “síndrome hepatocelular”. Podem cursar de forma aguda ou tornarem-se crônicas, sendo a fase aguda autolimitada, com duração média de 02 meses, tendo seu período máximo até 06 meses; a forma crônica é caracterizada por um período maior que 06 meses com o vírus no organismo, causando repetidas e incessantes agressões aos hepatócitos. A patologia cursa oligossintomática até que o paciente desenvolva sintomas característicos como ascite e encefalopatia hepática; outras formas de descobrir que o indivíduo é portador de uma HV são em testagens sanguíneas durante doações de hemocomponentes, exames de pré-natal, candidatos ao programa de hemodiálise e em campanhas de testagem rápida. Com esse estudo pôde-se delinear o perfil dos grupos de risco mais vulneráveis, tornando-se possível desenhar estratégias de prevenção, visando minimizar a taxa de contágio e episódios epidêmicos atingindo a meta global “NOHep” da OMS para erradicação das hepatites virais como problema de saúde pública até 2030.

show abstract

“…Belonging to the hepadnaviridae family with tropism for liver cells, and with humans as its natural host (2) , HBV has a genome composed by a deoxyribonucleic acid (DNA) and a set of proteins that forms specific antigens, with emphasis to: the surface antigen (HBsAg), used as diagnostic reference; the e antigen (HBeAg), which is related to the viral replication activity; and the core antigen (HBcAg), which, through the immunoglobulins M and G (IgM e IgG), indicates infectionrelated temporality (6)(7) . HDV, in view of the complex structure of HBV, consists of a single open reading frame of ribonucleic acid (RNA) and needs HBsAg to infect cells and assemble new viral structures (8)(9) .…”

Section: Introductionmentioning

confidence: 99%

Hepatitis B and Delta: clinical aspects of patients in the Brazilian Western Amazonia

et al. 2019

Self Cite

View full text Add to dashboard Cite

Objective: to analyze clinical, serological, biochemical and hematological aspects in patients infected with the hepatitis B (HBV) and Delta (HDV) viruses. Method: cross-sectional, descriptive and retrospective study, performed with patients chronically infected with HBV and superinfected with HDV. Results: among the 112 patients selected, 74% were monoinfected with HBV (Group HBV) and 26% were superinfected with HDV (Group HBV+HDV). There was no difference in gender distribution. The average age was 36 years with standard deviation of ±12 years. The symptoms and signs presented a higher proportion in Group HBV+HDV (p=0.001). In both groups, most patients had non-reactive AgHBe. The records of biochemical and hematologic changes showed highest proportion in Group VHB+VHD Group (p<0.05). Conclusion: the study found that patients were in clinical stages of the disease different from those in the initial examination for monitoring their chronic condition. The clinical profile suggests greater severity of liver disease among the patients superinfected with HDV.

show abstract

Evidências científicas sobre a hepatite Delta no Brasil: revisão integrativa da literatura

Cited by 5 publications

References 52 publications

Hepatitis mortality in Brazil and regions, 2001–2020: temporal trend and spatial analysis

Hepatitis mortality in Brazil and regions, 2001–2020: temporal trend and spatial analysis

Panorama das hepatites virais: um estudo atual

Hepatitis B and Delta: clinical aspects of patients in the Brazilian Western Amazonia

Contact Info

Product

Resources

About